
RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.

RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.

Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.

From HPV vaccination to PCOS management, this quiz is designed for primary care providers who want to stay ahead in women's health.
A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.
When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.

Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

Your daily dose of the clinical news you may have missed.

The CDC recommendation pertains to all international travel, regardless of destination, as a result of rising case numbers in the US.

ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.

Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.

Lyra Pharmaceuticals designed the implant, which provides 6 months of continuous delivery of the anti-inflammatory mometasone furoate.

Your daily dose of the clinical news you may have missed.

Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.

Interim results from COURAGE trial suggest combining semaglutide with muscle-preserving antibodies significantly enhances fat loss while preserving lean mass in obesity treatment.

Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.

Moderna's mRNA-1283 vaccine gains FDA approval for high-risk groups, following a significant shift in COVID-19 vaccination guidelines by federal health agencies.

Kennedy over 2 weeks has introduced changes in vaccination recommendations and research policy that undermine already tenuous public trust and understanding.